Novavax, Inc. Forecast, price target & analysts
Novavax, Inc. Target price 2025 - Analyst rating & recommendation
Novavax, Inc. Classifications & Recommendation:
Novavax, Inc. Price Target
| Target Price | $18.36 |
| Price | $6.30 |
| Potential |
191.43%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Novavax, Inc. 2026 .
The average Novavax, Inc. target price is $18.36.
This is
191.43%
register free of charge
$26.25
316.67%
register free of charge
$6.06
3.81%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Novavax, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Novavax, Inc. stock has an average upside potential 2026 of
191.43%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 0.68 | 1.07 |
| 30.65% | 56.85% | |
| EBITDA Margin | -26.89% | 45.67% |
| 48.23% | 269.83% | |
| Net Margin | -27.49% | 39.80% |
| 50.39% | 244.80% |
9 Analysts have issued a sales forecast Novavax, Inc. 2025 . The average Novavax, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Novavax, Inc. EBITDA forecast 2025. The average Novavax, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Novavax, Inc. Analysts have issued a net profit forecast 2025. The average Novavax, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.23 | 2.63 |
| 77.26% | 313.82% | |
| P/E | 2.40 | |
| EV/Sales | 0.48 |
9 Analysts have issued a Novavax, Inc. forecast for earnings per share. The average Novavax, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current Novavax, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | May 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| Jefferies |
Locked
➜
Locked
|
Locked | Oct 16 2024 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Oct 10 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 12 2024 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Oct 16 2024 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Oct 10 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
